A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System

被引：0
|
作者：
Altman, Keith [1 ]
Budny, Renata [2 ]
机构：
[1] Law Off Keith Altman, Massapequa Pk, NY USA
[2] New York City Coll Technol, Brooklyn, NY USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
744
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [41] Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases
    Mukai, Ririka
    Hasegawa, Shiori
    Umetsu, Ryogo
    Nakao, Satoshi
    Shimada, Kazuyo
    Uranishi, Hiroaki
    Masuta, Mayuko
    Suzuki, Honami
    Nishibata, Yuri
    Nakamura, Mitsuhiro
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 285 - 291
  • [42] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [43] Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system
    Nicholls, Connie
    Chyou, Te-Yuan
    Nishtala, Prasad S.
    INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE, 2023, 34 (01): : 63 - 73
  • [44] Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
    Sonawane, Kalyani B.
    Cheng, Ning
    Hansen, Richard A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 682 - 690
  • [45] Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
    Wang, Shiyi
    Wang, Xiaojian
    Ding, Jing
    Zhang, Xudong
    Zhu, Hongmei
    Fan, Yihong
    Sun, Changbo
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [46] COMMONLY REPORTED ADVERSE EVENTS ASSOCIATED WITH ANTICOAGULANTS USING FDA ADVERSE EVENT REPORTING SYSTEM DATABASE 2012-2018
    Costa, L.
    Hincapie, A.
    Guo, J. J.
    VALUE IN HEALTH, 2019, 22 : S163 - S163
  • [47] Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system
    Du, Yikuan
    Zhang, Mengting
    Chen, Mianhai
    Hu, Mianda
    Zeng, Wenqi
    Cai, Xiaolin
    Zhang, Weichui
    Zhu, Jinfeng
    Zhong, Mingjun
    Liu, Yi
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [48] Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
    Fukuda, Akiho
    Tahara, Kohei
    Hane, Yuuki
    Matsui, Toshinobu
    Sasaoka, Sayaka
    Hatahira, Haruna
    Motooka, Yumi
    Hasegawa, Shiori
    Naganuma, Misa
    Abe, Junko
    Nakao, Satoshi
    Takeuchi, Hirofumi
    Nakamura, Mitsuhiro
    PLOS ONE, 2017, 12 (09):
  • [49] ADVERSE EVENTS ASSOCIATED WITH COLCHICINE DRUG INTERACTIONS: ANALYSIS OF THE PUBLIC VERSION OF THE FDA ADVERSE EVENT REPORTING SYSTEM
    Almalki, Z.
    Guo, J. J.
    Kelton, C. M.
    Wigle, P. R.
    VALUE IN HEALTH, 2013, 16 (03) : A218 - A218
  • [50] Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
    Yang, Jingrong
    You, Mengfan
    Wang, Jingxin
    Sun, Rongfei
    Han, Lili
    Liu, Xiaonan
    Niu, Kaibin
    Xing, Kaidi
    Sun, Juanping
    Su, Wenge
    Wang, Yifei
    FRONTIERS IN PHARMACOLOGY, 2025, 16
12345